Biopharmaceutical R&D is characterized by long cycle, high investment and high risk. Early evaluation mechanisms based entirely on the functional activity ranking of candidate molecules have led to a number of new drug molecules encountering insurmountable challenges in process development, production, and transportation, and ultimately having to regretfully withdraw from the market.

Intellective Bio with the experience of developability research on 100+ molecules, will help customers to screen molecules with better developability and stability for advancement.